

# Very Early Pouchitis is Associated with an Increased Likelihood of **Chronic Inflammatory Conditions of the Pouch**

Scott Esckilsen<sup>1</sup>, Bharati Kochar<sup>2,3</sup>, Kimberly N. Weaver<sup>4,5</sup>, Hans H. Herfarth<sup>4,5,6</sup>, Edward L. Barnes<sup>4,5,6</sup> Chapel Hill, Chapel Hill, NC

<sup>1</sup>Department of Medicine, University of North Carolina at Chapel Hill, NC, <sup>2</sup>Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, <sup>3</sup>Clinical Translational Epidemiology Unit, The Mongan Institute, Boston, MA, <sup>4</sup>Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, NC, <sup>5</sup>Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC, <sup>6</sup>Center for Gastrointestinal Biology at the second at t

## Background

Chronic inflammatory conditions of the pouch are common after colectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC).

After IPAA for UC approximately 17% of patients will develop chronic antibiotic dependent pouchitis (CADP) while 10% will develop Crohn's-like disease of the pouch (CLDP).

Despite the high prevalence of these inflammatory complications after IPAA surgery, there remains a lack of knowledge regarding the risk factors for the future development of these complications.

### Aim

To investigate the relationship between very early pouchitis, defined as pouchitis within the first 180 days of the final stage of IPAA surgery, and the future development of CADP and CLDP.

### Methods

**Design:** Retrospective cohort study

**Population:** Adults who underwent proctocolectomy with IPAA for UC at UNC between 1/1/2004 and 12/31/2016.

Primary Outcome: The development of CADP in patients with very early pouchitis.

Secondary outcomes: The development of CLDP in patients with very early pouchitis.

**Analysis:** Multivariable logistic regression was used to evaluate the relationship between very early pouchitis and the development of CADP and CLDP.

### Results

 
 Table 1. Univariate comparison of demographic and clinical
 characteristics of patients with and without pouchitis in the

two years following an IPAA	۱.					
	Patients without early pouchitis		Patients with early pouchitis		p-value	0.94 – 10.8 years).
	(n=4	189)	(n=1)	137) IOD		Table 2. Odda of developing abrevia antibiotic demondant
Age of ourgent, in veere					0.004	Table 2. Odds of developing chronic antibiotic dependent
Age at surgery, in years	40.3	20.0-02.4	43.1	33.7-54.5	0.094	pouchitis after ileal pouch-anal anastomosis for
Disease duration prior to surgery	5.9	2.2-14.2	0.3	1.90-13.0	0.004	ulcerative colitis
Mala Say	11	70 50 0		% E 4 7	0.400	
	249	50.9	75	54.7	0.429	Unadjusted Odds Adjusted Odds
	124	00.2	101	90.0	0.923	Ratio (95% CI) Ratio (95% CI)
Wille Non-White	424	09.3 10.7	121	09.0 11.0		Very Early Pouchitis 3.61 (2.18 – 5.96) 3.65 (2.19 – 6.10)
	51	10.7	13	11.0	0.000	(acute pouchitis within 180 days of
	6	1.4	1	5.6	0.006	IPAA)
Family history of CD or UC	83	16.2	14	20.0	0.421	Duration of ulcerative colitis prior to
Indication for surgery	070	70.0		00.4	0.059	colectomy
Nedically-refractory colitis	376	/6.9	118	86.1		≤2 years 0.75 (0.33 - 1.74) 0.78 (0.34 - 1.79)
Dysplasia of cancer	12	14.7	11	8.0		3-5 years Reference Reference
	41	0.4	0	5.6		$\begin{array}{c} \textbf{6-10 years} \\ \textbf{1.28} (0.58 - 2.82) \\ \textbf{1.19} (0.53 - 2.66) \\ \textbf{1.69} (0.95 - 2.34) \\ \textbf{1.59} (0.76 - 2.07) \\ \textbf{1.69} (0.95 - 2.34) \\ \textbf{1.69} (0.76 - 2.07) \\ \textbf{1.69}$
						1.00 (0.85 – 3.31) 1.53 (0.76 – 3.07)
Disease extent prior to surgery					0.405	
Proctitis	23	5.0	3	2.3		Primary sclerosing cholangitis         4.78 (1.81 – 12.5)         3.97 (1.44 – 11.0)
Left-sided colitis	133	29.1	40	30.8		
Extensive colitis	301	65.9	87	66.9		
Stages involved in IPAA Surgery					0.977	Note: All factors included in the multivariable model are shown
1	92	18.9	24	17.5		chovo
2	173	35.5	51	37.2		above.
Modified 2	183	37.5	11	37.2		
3	40	8.2	51	8.0		
Abscess or pelvic sepsis after IPAA	94	19.2	23	16.8	0.518	
	20	7.0	0	5.0	0 4 4 4	
evidence of an IPAA leak immediately	38	7.8	8	5.8	0.444	
Anter Surgery	10	0.7	0	A A	0.000	Table 3. Odds of devloping Crohn's like disease of the
Primary Scierosing Cholangitis	13	2.1	Ю	4.4	0.299	pouch after an ileal pouch-anal anastomosis for ulcerative
Suptomic omine collectomy	200	77 7	445	00.0	0.440	colitis
Systemic aminosalicylate	380	(1.1	115	83.9	0.113	
This and a minosalicylate	230	47.0	12	52.6	0.253	Unadiusted Odds Adjusted
Thiopurine	299	61.2	91	66.4	0.256	Ratio (95% CI) Odds Ratio
Methotrexate	58	11.9	9	6.6	0.077	
Anti-TNF	252	51.5	69	50.4	0.809	Very Early Pouchitie 278 (158 4 92) 277 (154
Vedolizumab	11	2.3	6	4.4	0.175	2.70(1.30 - 4.02) 2.77(1.34 - 4.02)
Cyclosporine	13	2.7	13	9.5	< 0.001	(acute pouchitis within 160 days of 4.98)
Prednisone use at the time of last	192	39.3	58	42.7	0.487	
stage of surgery						
						Delayed Pouch Creation 1.21 (0.70 – 2.08) 1.27 (0.72 – 2.24)
Anti-tumor necrosis factor alol	ha (anti-TI	NF): Croh	n's disea	se (CD):		Eamily history of CD or LIC $220(118, 411) 214(112)$
ileal nouch-anal anastomosis	$(IP\Delta \Delta)$ in	torquartile	rango /l	()		
	(IF ~~), III	iei quai ille	= range (I	ωix <i>)</i> ,		4.05)

ulcerative colitis (UC)

Among 626 patients undergoing IPAA for UC, 137 (22%) developed very early pouchitis, 75 (12%) developed CADP, and 59 (9%) developed CLDP The median duration of follow up was 5.18 years (IOR

Note: All factors included in the multivariable model are shown above.

pouch diseases.

fractory UC or UC-

Very early pouchitis is associated with an increased risk developing CADP and CLDP.

The identification of very early pouchitis has the potential to serve as a unique risk factor for future chronic inflammatory conditions of the pouch.

Future studies should focus on treating very early pouchitis as an individual phenotype to prevent future chronic pouch related disorders.

### **Contact information**

- Scott Esckilsen:



### Figure 1. Disease progression in chronic inflammatory



### Conclusions

scott.esckilsen@unchealth.unc.edu Edward Barnes: <a href="mailto:edward\_barnes@med.unc.edu">edward barnes@med.unc.edu</a>

Funded by: National Institutes of Health; Award K23DK127157-01